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The prognosis for advanced gastric cancer is poor: less than 10–15% of patients 
with metastases live for more than 2 years. Trastuzumab and ramucirumab have 
resulted in modest improvements in overall survival for patients with HER2-positive 
gastric cancer and in the second-line setting, respectively (1–2). However, these 
drugs are notable for their success in a field in which there have been many failures 
(1–4). Within this challenging therapeutic context, the results of the KEYNOTE-012 
study by Kei Muro and colleagues (5) are promising. 
In KEYNOTE-012, patients with PD-L1-positive advanced gastric cancer were 
treated with pembrolizumab, an anti-PD-1 antibody, until progression or intolerable 
adverse events. 65 (40%) of 162 patients screened were PD-L1-positive, and 39 
(24%) patients were enrolled in this international phase 1b study. Impressively, 17 
(53%) of 32 patients with at least one post-baseline tumour assessment had 
evidence of tumour regression, and eight (22%) of 36 evaluable patients had a 
confirmed partial radiological response. Consistent with immunotherapy trials in 
other cancers, these responses were sustained; the median duration of response 
was 40 weeks and four (11%) of 36 evaluable patients who had a response had not 
progressed at the time of reporting. Toxicity was as expected, with immune-related 
adverse events occurring in nine (23%) patients. No patients discontinued therapy 
due to an immune-mediated adverse event; this result compares favourably with 
second-line chemotherapy trials in which treatment discontinuation due to adverse 
events ranges from 11% to 30% (4,6). Muro and colleagues show that in KEYNOTE-
012, survival was similar between Asian and non-Asian patients, a reassuring finding 
given that recent international gastric cancer trials have been affected by regional 
variations in survival (3,4). 
Screening for KEYNOTE-012 was done with a prototype immunohistochemistry 
assay for PD-L1. To be eligible to participate, patients needed at least 1% PD-L1 
expression in tumour cells, immune cells, or both cell types. PD-L1 status was then 
reassessed with a different assay. The results of the second assay suggest that PD-
L1 expression on immune cells, but not tumour cells, is associated with response to 
pembrolizumab in gastric cancer. Secondly, eight of the 35 patients with assessable 
biopsies were classified as PD-L1-negative on repeat testing. These results are a 
testament to the complexity of PD-L1 analysis in general, and gastric cancer 
biomarker assessment in particular. This discordance could be due to dynamic 
changes in PD-L1 expression following treatment, assay variability, or gastric cancer 
heterogeneity. Consequently, it is unclear whether the radiological responses that 
have been reported in seemingly PD-L1-negative patients treated with anti-PD1 
therapies in non-biomarker selected trials are indicative of underlying heterogeneity 
of biomarker expression or a true absence of association between the biomarker and 
response (7). Further exploration will be needed to identify the best method to 
assess PD-L1 and whether it is a true predictive biomarker for immunotherapy in 
gastric cancer. The authors also presented preliminary results with their interferon γ 
gene expression signature, as a tissue-of-origin independent predictive biomarker, 
which, if validated, could be helpful in the future to circumvent these 
immunohistochemistry assay-related challenges.  
KEYNOTE-012 presents several thought-provoking results that cannot be definitively 
resolved by this small study. First, the interaction between previous chemotherapy 
treatment and the efficacy of pembrolizumab is unclear. Although several patients 
with a response had received one or fewer lines of chemotherapy prior to 
pembrolizumab, encouragingly, most (63%) responding patients had received two or 
more prior anticancer therapies. However, a small early phase trial such as 
KEYNOTE-012 cannot take into account the short life expectancy of many advanced 
gastric cancer patients, which might make the relatively slow response rates and 
occasional pseudoprogression associated with immunotherapy challenging to adopt. 
The optimum setting in which to treat patients with gastric cancer with 
immunotherapy will be established by several ongoing trials. Second, although 
microsatellite unstable gastric cancer should, theoretically, be an easy target for 
immunotherapy, this hypermutated phenotype predicted response in only half of the 
patients with microsatellite instability treated with pembrolizumab in KEYNOTE-012. 
This subset represents up to 22% of patients with gastric cancer and merits further 
investigation (8). Finally, the metrics by which the success of immunotherapy clinical 
trials for gastric cancer should be assessed require careful consideration. The 
proportion of patients achieving a response in KEYNOTE-012 is smaller than that in 
the RAINBOW trial of the combination of paclitaxel and ramucirumab—in fact, by a 
purely statistical definition KEYNOTE-012 is a negative trial. Neither do the 
unremarkable progression-free survival results account for the substantial overall 
survival benefi t for patients who responded to treatment (5). Attention to each of 
these issues is warranted in ongoing randomised clinical trials.  
Trials of anti-CTLA-4 and anti-PD-1 therapy have been extremely successful in 
melanoma, which risks making the results of KEYNOTE-012 seem less impressive 
by comparison. However, gastric cancer causes three times as many deaths as 
melanoma does each year worldwide, arguably making these results more important 
(9). The results of the current study are an encouraging first step towards the 
development of a therapy that can result in long-term remission for a disease that, 
for most patients, currently has no realistic hope for a cure. 
